DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
George Frey REFILE - 2 Spiegel - 2 Karl Broich - 2 Ludwig Burger - 2 Miranda Murray - 2 Lilly - 1 Eli Lilly's - 1 tirzepatide - 1
Top related locs:
Provo , Utah U.S United States Germany FRANKFURT Europe Britain Belgium
Top related orgs:
Novo Nordisk - 2 Pharmacy - 2 REUTERS - 2 Novo Nordisk's - 2 Spiegel - 2 Thomson - 2 BfArM - 1 EU - 1

Search resuls for: "Karl Broich"


2 mentions found


☆ German regulator eyes Ozempic export ban amid shortages across Europe
  + stars: | 2023-11-15 | by ( Ludwig Burger | ) www.reuters.com   time to read: +5 min
Use of Ozempic for weight loss has caused shortages across Europe. Novo Nordisk, which has earmarked $6 billion to boost production in Denmark, said last week the industry was far from being able to produce enough weight-loss drugs to meet global demand. The German association of drug wholesale distributors PHAGRO said in a statement that there was no certainty that exports were causing the shortages. Portugal, Poland, Romania, Belgium, Slovakia and Spain, in turn, have rules in place that likely make it impossible to export the drug, Affordable Medicines said. It also urged "all relevant actors" not to export the drugs.
Persons: George Frey REFILE, Spiegel, Lilly, Karl Broich, Eli Lilly's, tirzepatide, BfArM's Broich, Broich, PHAGRO, Germany's BfArM, Ludwig Burger, Miranda Murray, Patricia Weiss, Matthias Williams, Sharon Singleton Organizations: Novo Nordisk, Pharmacy, REUTERS, BfArM, EU, Novo Nordisk's, Spiegel, European Union, Medicines, Thomson Locations: Provo , Utah, U.S, FRANKFURT, United States, Europe, Britain, Belgium, Germany, Norway, Denmark, Medicines Europe, Austria, France, Greece, Czech Republic, Portugal, Poland, Romania, Slovakia, Spain, Frankfurt, Berlin
☆ German drug regulator considering export ban on Ozempic
  + stars: | 2023-11-15 | by ( ) www.reuters.com   time to read: +1 min
[1/2] A box of Ozempic, a semaglutide injection drug used for treating type 2 diabetes and made by Novo Nordisk, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey REFILE - CORRECTING MONTH/File Photo Acquire Licensing RightsCompanies Novo Nordisk A/S FollowBERLIN, Nov 15 (Reuters) - The head of Germany's drug regulator BfArM is considering an export ban on Novo Nordisk's (NOVOb.CO) diabetes drug Ozempic, which is in high demand for its weight-loss benefits, to prevent a further worsening of a supply shortage. There is a risk of Ozempic being moved out of the country because it is cheaper there than in many other countries, BfArM president Karl Broich told Spiegel magazine. "We know that some of the syringes that are supplied to Germany for our diabetes patients are channelled to other European countries or the United States," he told Spiegel on Wednesday. We need the medication for the care of diabetes patients and not as a lifestyle drug."
Persons: George Frey REFILE, Karl Broich, Spiegel, Miranda Murray, Ludwig Burger Organizations: Novo Nordisk, Pharmacy, REUTERS, Novo Nordisk's, Spiegel, Ludwig Burger Our, Thomson Locations: Provo , Utah, U.S, Germany, United States
0 next >>
Total: 2